Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 19 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezabenlimab (Primary) ; Miptenalimab (Primary)
  • Indications Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 30 Mar 2024 Results assessing safety, maximum tolerated dose (MTD), pharmacokinetics and antitumour activity of ezabenlimab in Study 1381.1 (NCT02952248), Study 1381.4 (NCT03433898) and Study 1381.3 (NCT03780725) published in the Cancer Immunology Immunotherapy.
    • 27 Jul 2023 Status changed from active, no longer recruiting to completed.
    • 10 Jul 2023 Planned End Date changed from 4 Aug 2023 to 19 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top